Financial Performance - The company's operating revenue for 2024 reached ¥1,819,075,569.77, representing a 35.64% increase compared to ¥1,341,074,347.86 in 2023[16]. - The net profit attributable to shareholders for 2024 was ¥220,261,152.36, up 31.05% from ¥168,069,329.73 in 2023[16]. - The net profit after deducting non-recurring gains and losses for 2024 was ¥162,128,382.52, a 39.58% increase from ¥116,155,426.61 in 2023[16]. - The net cash flow from operating activities for 2024 was ¥320,130,370.41, showing a significant increase of 103.99% compared to ¥156,936,759.28 in 2023[16]. - The basic earnings per share for 2024 was ¥1.7729, reflecting a 31.65% increase from ¥1.3467 in 2023[16]. - Total assets at the end of 2024 amounted to ¥3,918,827,588.40, a 6.03% increase from ¥3,695,914,140.16 at the end of 2023[16]. - The net assets attributable to shareholders at the end of 2024 were ¥3,119,631,283.07, up 1.19% from ¥3,082,975,745.74 at the end of 2023[16]. - The company reported a total revenue of 58,132,769.84, an increase from 51,913,903.12 in the previous period, reflecting a growth of approximately 23.5%[22]. - The revenue from the mold and injection industry was ¥1,204,648,145.77, accounting for 66.23% of total revenue, with a year-on-year growth of 27.05%[60]. - The health appliance sector generated ¥537,777,972.42, which is 29.56% of total revenue, showing a significant increase of 42.83% from the previous year[60]. - The overseas revenue accounted for 43.23% of total revenue, increasing by 44.64% from the previous year[60]. Dividend Distribution - The company plans to distribute a cash dividend of 6 RMB per 10 shares (including tax) to all shareholders, with no bonus shares issued[3]. - The board of directors has approved the profit distribution plan based on the total number of shares minus those in the repurchase account[3]. - The profit distribution plan for 2024 includes cash dividends of RMB 6 per 10 shares, with no stock dividends or capital reserve transfers[179]. - The total cash dividend amount for the current year is RMB 74,880,000, representing 100% of the profit distribution total[178]. - For the first half of 2024, the company intends to distribute cash dividends of RMB 5 per 10 shares, amounting to RMB 62,185,814.50[175]. Strategic Acquisitions and Market Position - The company completed the acquisition of Yuke Plastic (Xiamen) Co., Ltd. in May 2024, positioning itself as a primary supplier for leading domestic new energy manufacturers[31]. - The company has established a global production base with facilities in Xiamen, Shanghai, Tianjin, Quanzhou, Germany, Malaysia, Mexico, and Vietnam, enhancing its market reach[26]. - The company has established long-term partnerships with major clients across various sectors, including automotive, outdoor home, electronics/robotics, and health appliances, enhancing its market presence[55]. - The company has established subsidiaries in the United States and Singapore as part of its marketing network expansion[102]. - The company has established subsidiaries in Germany, Malaysia, Mexico, Singapore, the United States, and Vietnam to expand overseas markets, facing potential operational risks due to differing legal and cultural environments[119]. Research and Development - The company has invested significantly in R&D, with a total of 501 authorized patents, including 31 invention patents, enhancing its long-term competitive advantage[50]. - The company is focusing on the development of ultra-precision injection molds, aiming to enhance production efficiency and reduce costs through innovative temperature control methods[74]. - Research is being conducted on high-gloss, spray-free injection molding technology to improve surface quality and mold lifespan, addressing key technical bottlenecks[74]. - The company is implementing a new design for a shaft insert positioning mechanism to ensure accurate alignment and reduce defect rates during production[74]. - R&D investment amounted to ¥86,286,432.38 in 2024, an increase of 24.63% from ¥69,251,198.07 in 2023[76]. - The number of R&D personnel increased by 23.26% to 408 in 2024 from 331 in 2023[75]. Operational Efficiency and Management - The company has implemented advanced manufacturing equipment and MES systems to enhance production efficiency and flexibility[52]. - The company has developed an information management system that integrates resources across procurement, production, sales, and R&D, improving operational efficiency[58]. - The company has established a comprehensive production line for precision injection molds, injection parts, and health products, creating a synergistic effect across the supply chain[43]. - The production of injection parts follows a "sales-driven production" model, aligning production plans with sales orders and inventory levels[47]. - The company has a complete procurement, R&D, production, and sales system, ensuring its ability to operate independently in the market[136]. Governance and Compliance - The company has held two shareholder meetings during the reporting period, ensuring compliance with legal procedures and facilitating participation from minority shareholders[125]. - The governance structure of the company has improved, ensuring independence from the controlling shareholder and maintaining operational autonomy[126]. - The company maintains complete independence in assets, personnel, finance, organization, and business from its controlling shareholders[131]. - The company has established specialized committees under the board to enhance governance and promote sustainable development[127]. - The board of directors has been diligent in their responsibilities, ensuring compliance with relevant laws and regulations throughout the reporting period[165]. Employee Management and Compensation - The total number of employees at the end of the reporting period is 3,566, with 2,594 in production, 134 in sales, 408 in technology, 84 in finance, and 346 in administration[171]. - The company has established a competitive compensation system to enhance employee motivation and align with business growth[172]. - The company has implemented a comprehensive training program to foster talent development and enhance employee skills[173]. - The company has established a performance evaluation mechanism for senior management, linking their compensation to annual performance targets and overall company performance[189]. Risks and Challenges - The company faces risks from fluctuating international trade tariffs, which have impacted operations, and will diversify its business to reduce dependence on single markets[117]. - The overall gross margin has slightly declined compared to the previous year due to rising labor costs and raw material price fluctuations, prompting the company to enhance product quality and innovation efforts[118]. - The company is addressing management challenges arising from rapid expansion by strengthening human resource management and recruiting high-skilled talent[120].

唯科科技（301196）公告，2024年营业收入18.19亿元，同比增长35.64%。归属于上市公司股东的净利 润2.2亿元，同比增长31.05%。基本每股收益1.77元/股，同比增长31.65%。公司拟向全体股东每10股派 发现金红利6元(含税)，送红股0股(含税)，以资本公积金向全体股东每10股转增0股。 ...

证券代码：301196 证券简称：唯科科技 公告编号：2025-008 厦门唯科模塑科技股份有限公司 关于使用部分闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 厦门唯科模塑科技股份有限公司（以下简称"公司"）于 2024 年 4 月 21 日召开第二届董事会第十次会议、第二届监事会第九次会议及 2024 年 5 月 14 日召开 2023 年度股东大会，审议通过了《关于使用部分闲置募集资金进行现金 管理的议案》，同意公司在不影响募投项目建设和募集资金使用的情况下，使用 不超过人民币 9 亿元（含）的闲置募集资金进行现金管理，用于购买安全性高、 流动性好的保本型金融产品或结构性存款等理财产品，使用期限为自公司股东大 会审议通过之日起不超过 12 个月（含），在上述额度及期限内可循环滚动使用。 具体内容详见公司于 2024 年 4 月 23 日在巨潮资讯网（www.cninfo.com.cn）披 露的《关于使用部分闲置募集资金进行现金管理的公告》。现将近期使用部分闲 置募集资金进行现金管理的进展情况公告如下： 一、 新增现金管 ...

Investment Rating - The report maintains a "Buy" rating for the companies mentioned, indicating a positive outlook for their performance in the market [11][50]. Core Insights - The report highlights the launch of Alibaba's Qwen2.5-Omni, a new flagship multimodal model designed for comprehensive multimodal perception, capable of processing various inputs including text, images, audio, and video [4][19]. - DeepSeek-V3 has been released with significant performance improvements, becoming the strongest non-inference model, and is expected to accelerate AI applications in vertical fields [11][26]. - Anthropic has completed a $3.5 billion financing round, raising its valuation to $61.5 billion, showcasing the rapid growth and competition in the AI sector [36][37]. Summary by Sections 1. Computing Power Dynamics - Computing power rental prices remain stable, with specific pricing details provided for various configurations [18][21]. - Alibaba's Qwen2.5-Omni is positioned as a significant advancement in the AI landscape, emphasizing its capabilities in real-time interaction and multimodal processing [19][20]. 2. AI Application Dynamics - Gemini's search traffic increased by 6.85%, indicating growing interest in AI applications [25]. - The new version of DeepSeek, with 685 billion parameters, has shown remarkable performance improvements and is now open-sourced under the MIT license, enhancing its accessibility and potential for commercial applications [26][27]. 3. AI Financing Trends - Anthropic's recent funding round of $3.5 billion reflects the intense competition and rapid capital influx in the AI sector, with a total of over $4.5 billion raised in just three months [36][37]. 4. Investment Recommendations - The report suggests focusing on companies like 嘉和美康 (688246.SH), 科大讯飞 (002230.SZ), and others that are positioned to benefit from advancements in AI technology and applications [11][50].

Investment Rating - The report assigns a "Strong Buy" rating for the company, indicating a predicted increase of over 20% relative to the benchmark index in the next 12 months [4][8]. Core Views - The company is a leading player in the precision injection molding industry, with diversified development driving revenue growth. The main business includes the R&D, design, manufacturing, and sales of precision injection molds, extending into injection parts and health products [3][4]. - In Q1-Q3 of 2024, the company achieved a revenue increase of 45.56% year-on-year to 1.339 billion yuan, with a net profit increase of 62.25% to 177 million yuan, showcasing strong performance [3][4]. - The company has established long-term partnerships with well-known firms such as Aifumei, Bosch, and BorgWarner, enhancing its market presence in the precision injection mold sector [3][4]. Revenue and Profit Forecast - The company is expected to achieve revenues of 1.765 billion, 2.156 billion, and 2.606 billion yuan for the years 2024, 2025, and 2026, respectively, with corresponding net profits of 259 million, 290 million, and 346 million yuan [4][8]. - The projected PE ratios for the years 2024, 2025, and 2026 are 27, 24, and 20 times, respectively [4][8]. Business Segments - Health Products: Expected revenue growth rates of 40%, 15%, and 15% for 2024-2026, with a stable gross margin of 21% [6]. - Precision Molds: Anticipated revenue growth rates of 15%, 20%, and 20% for the same period, with gross margins of 45%, 43%, and 41% [6]. - Injection Products: Forecasted revenue growth rates of 30%, 28%, and 25%, with gross margins of 32.5%, 33%, and 33% [6]. - Other Segments: Expected to see significant growth with revenue growth rates of 200%, 10%, and 10%, and gross margins of 16%, 18%, and 18% [6]. Market Position and Strategy - The company is actively expanding into the new energy sector, supplying injection parts for electric vehicles and becoming a Tier 1 supplier for major automotive brands [4][3]. - The company is also advancing its research in electronic skin technology, collaborating with global medical brands and developing innovative materials [4][3].

证券代码：301196 证券简称：唯科科技 公告编号：2025-007 厦门唯科模塑科技股份有限公司 关于使用部分闲置自有资金进行现金管理的进展公告 厦门唯科模塑科技股份有限公司（以下简称"公司"）于 2024 年 4 月 21 日召开第二届董事会第十次会议及 2024 年 5 月 14 日召开 2023 年度股东大会， 审议通过了《关于使用部分闲置自有资金进行现金管理的议案》，同意公司使用 不超过人民币 15 亿元（含）的闲置自有资金进行现金管理，用于购买安全性高、 流动性好的金融产品或结构性存款等理财产品，使用期限为自公司股东大会审议 通过之日起不超过 12 个月（含）。在上述额度及决议有效期内，可循环滚动使 用。具体内容详见公司 2024 年 4 月 23 日刊登于巨潮资讯网（www.cninfo.com.cn） 上的《关于使用部分闲置自有资金进行现金管理的公告》。现将近期使用部分闲 置自有资金进行现金管理的情况公告如下： 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、新增现金管理的基本情况 自 2024 年 11 月 4 日至本公告日，公司（含子 ...

证券代码：301196 证券简称：唯科科技 公告编号：2025-006 厦门唯科模塑科技股份有限公司 关于控股子公司在马来西亚购买土地并签订《土地购买协议》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 注册地：Ground Floor, Wisma Budiman Persiaran Raja Chulan 50200 Kuala Lumpur Wilayah Persekutuan Kuala Lumpur 一、交易概述 1、厦门唯科模塑科技股份有限公司（以下简称"公司"）为了落实、完善 公司国际化战略发展布局，加大市场辐射的深度和广度，同时为了进一步巩固、 提升与东南亚地区客户的合作关系，公司通过控股子公司唯科科技（马来西亚） 私人有限公司（Vork Technologies（Malaysia）SDN.BHD.）（以下简称"马来 西亚唯科"）在马来西亚购买土地并投资建设生产基地。2025 年 3 月 5 日，马 来西亚唯科与 SENAI AIRPORT CITY SDN. BHD.签订《土地购买协议》，使用自 有资金46,209,239林吉特购买 ...

Group 1: Company Overview - Weike Technology specializes in the research, design, manufacturing, and sales of precision injection molds, expanding into injection parts and health product production [2] - The company has developed into a "mold-integration" large-scale production enterprise, providing quality products and services to manufacturing companies in various sectors including automotive and electronics [2] - Since its establishment, Weike has focused on precision injection molds while actively extending its business to downstream products, components, and health small appliances [2] Group 2: Global Expansion - In 2018, Weike established an overseas production base in Germany to align with international standards and began global operations [2] - From 2019 onwards, the company has been building production bases and marketing service networks in Malaysia, Mexico, the USA, Singapore, and Vietnam, further expanding its global footprint [2] Group 3: Technological Innovation - Weike has over 500 patents, including 34 authorized invention patents, and has been recognized as a key enterprise in precision injection molds and a high-tech enterprise [3] - The company is focusing on technological innovation to drive growth and has been awarded various honors, including "National Enterprise Technology Center" and "National Specialized and New 'Little Giant' Enterprise" [3] Group 4: Research and Development - Weike collaborates with companies like DANFOSS to develop self-lubricating PEEK and PPS materials for plastic screw products [3] - The company is working on a bionic robot electronic skin project in partnership with AMBU, developing plastic human skin for laboratory and educational use [3] - Weike has developed samples of in-mold electronic products with flexible printed circuit boards, showcasing significant lightweight effects [3]

Company Overview - Weike Technology specializes in the research, design, manufacturing, and sales of precision injection molds and has expanded into the production and sales of injection parts and health products, becoming a "mold-integration" large-scale production enterprise [2][3] - The company has developed a global operational layout with production bases and marketing service points established in Malaysia, Mexico, the USA, Singapore, and Vietnam since 2019 [3] Technological Innovation - Weike Group holds over 500 patents, including 34 authorized invention patents, and has been recognized as a key backbone enterprise in precision injection molds and a national-level "specialized and innovative" small giant enterprise [3] Product Applications - The company supplies components for robotic joints to global motor companies like Nidec and Kollmorgen, with products made from PET reinforced materials known for their excellent mechanical properties [4] - Collaborations include developing core injection components for AI racing simulators and medical applications, such as plastic human skin for laboratory use [5] Market Growth - In the first three quarters of 2024, revenue growth was notable in the new energy, small home appliances, and outdoor home sectors, with new energy sales rapidly increasing since 2023 [11] - The company aims for a 20% year-on-year increase in net profit for 2025, with a net profit of 177 million yuan reported for the first three quarters of 2024 [11] Financial Position - As of the end of Q3 2024, the company had over 1.4 billion yuan in cash assets, primarily used for low-yield bank investments, while actively seeking suitable acquisition targets in downstream industries [11] Competitive Advantages - The transition from metal to plastic components offers significant advantages, including weight reduction (plastic parts can weigh less than one-fifth of metal parts) and higher processing efficiency [7] - The technical barriers in the robotic motor injection parts sector include mold processing precision and quality control consistency during mass production [8]

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [9]. Core Insights - The company focuses on precision injection molding and has diversified its business to include the production and sales of injection-molded parts and health products, establishing a "molding integration" production scale [4]. - The revenue for the first three quarters of 2024 reached 1.339 billion yuan, a year-on-year increase of 45.56%, while the net profit attributable to shareholders was 177 million yuan, up 62.25% year-on-year [4]. - The gross margin for the first three quarters of 2024 was 28.94%, and the net margin was 13.71%, reflecting a stable revenue growth due to a diversified business model [4]. Revenue Growth from New Energy Products - The new energy sector has become a key driver for revenue growth in 2024, with significant sales of injection-molded parts for electric vehicles and other related products [5]. - The company has become a primary supplier for major new energy vehicle brands, including Tesla and NIO, following the acquisition of Yuke Plastic [5]. - In the first half of 2024, revenue from injection-molded products reached 361 million yuan, a 34.20% increase compared to the same period last year [5]. Supply to Global Motor Giants - The company supplies components for robots, including motor parts and gears, to major global manufacturers like Kollmorgen and Nidec [8]. - Nidec is a comprehensive motor manufacturer with over 300 branches worldwide, while Kollmorgen specializes in motion control systems [8]. Earnings Forecast - The projected revenues for 2024, 2025, and 2026 are 1.645 billion yuan, 2.039 billion yuan, and 2.541 billion yuan, respectively, with corresponding EPS of 1.66 yuan, 2.02 yuan, and 2.44 yuan [9]. - The current stock price corresponds to PE ratios of 25.5, 21.1, and 17.4 for the years 2024, 2025, and 2026, respectively [9].